EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
EntreMed, Inc. (Nasdaq: ENMD) announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study. The study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.